Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)

Cell Cycle

Volumn 8, Issue 21, 2009, Pages 3562-3570

  Glinskii, Anna B ^a   Glinsky, Gennadi V ^a   Lin, Hung Yun ^a   Tang, Heng Yuan ^a   Sun, Mingzeng ^a   Davis, Faith B ^a   Luidens, Mary K ^a   Mousa, Shaker A ^a   Hercbergs, Aleck H ^b   Davis, Paul J ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Cell survival genes; MDA MB 231 cells; Microarray; Tetraiodothyroacetic acid; Thyroid hormone

Indexed keywords

CASPASE 2; CATENIN; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; LEVOTHYROXINE; PROTEIN; PROTEIN BCL 2 L 14; PROTEIN MCL 1; RAS PROTEIN; TETRAIODOTHYROACETIC ACID; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE RAS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 70449718848     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.21.9963     Document Type: Article

References (28)

1. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004; 145:3265-3271
2. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146:2864-2871
3. Davis PJ, Davis FB, Leonard JL. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008; 29:211-218
4. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 275:21785-21788
5. Felding-Habermann B, O'Toole TM, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98:1853-1858 (Pubitemid 32165587)
6. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 2009; 106:10666-10671
7. Mousa SA, O'Connor L, Davis FB, Davis PJ. Proangiogenesis action of the thyroid hormone analogue 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin-mediated. Endocrinology 2006; 147:1602-1607
8. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 145:3265-3271
9. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008; 11:183-190
10. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008; 29:62-69 (Pubitemid 351201742)
11. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 2008; 11:269-276
12. Yalcin M, Lansing L, Dyskin E, Bharali DJ, Rebbaa A, Mousa SS, et al. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma. Anti-Cancer Res. In press.
13. Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Cathew RW, Moon RT. Chibby, a nuclear β-catenin-associated antagonist of the Wnt/wingless pathway. Nature 2003; 422:905-909 (Pubitemid 36520044)
14. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenesis action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 2005; 46:356-360
15. Mangale SS, Modi DN, Reddy KV. Identification of genes regulated by an interaction between αvβ3 integrin and vitronectin in murine decidua. Reprod Fertil Dev 2008; 20:311-319
16. Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-α-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 2009: 113:182-188
17. Lin HY, Davis PJ, Tang HY, Mousa SA, Luidens MK, Hercbergs AH, et al. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 2009; 8:1877-1882
18. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, Davis FB. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is antiapoptotic. Steroids 2007; 72:180-187 (Pubitemid 46273502)
19. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007; 9:63.
20. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. Regulation of β-catenin by a novel nongenomic action of thyroid hormone β receptor. Mol Cell Biol 2008; 28:4598-4608 (Pubitemid 351977757)
21. Yang M, Chen T, Han C, Li N, Wan T, Cao X. Rab7b, a novel lysosome-associated small GTPase, is involved in monocytic differentiation of human acute promyelocytic leukemia cells. Biochem Biophys Res Commun 2004; 318:792-799 (Pubitemid 38624223)
22. Ren B, Yen KO, Lawler J, Khoaravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765:178-188
23. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, et al. L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009; 296:980-991
24. Lin HY, Zhang S, West BL, Tang HY, Passaretti T, Davis FB, Davis PJ. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-β1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 2003; 42:7571-7579 (Pubitemid 36735834)
25. Glinsky GV, Glinskii AB, Berezovskaya O. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115:1503-1521
26. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113:913-923 (Pubitemid 38544150)
27. Glinsky GV, Higashiyama T, Glinskii AB. Classification of human breast cancer using gene expression profiling as a comoponent of the survival predictor algorithm. Clin Cancer Res 2004; 10:2272-2283 (Pubitemid 38445684)
28. Glinsky GV, Krones-Herzig A, Glinskii AB, Gebauer G. Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Mol Carcinog 2003; 37:209-221 (Pubitemid 36959537)